Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Abivax SA - American Depositary Shares
(NQ:
ABVX
)
73.20
-7.45 (-9.24%)
Delayed Quote
Updated: 4:00 PM EST, Nov 20, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Abivax SA - American Depositary Shares
< Previous
1
2
3
Next >
Abivax Statement on Short Seller Report
November 20, 2026
From
Abivax
Via
GlobeNewswire
Abivax to Participate in Upcoming Fall Investor Conferences
November 02, 2026
From
Abivax
Via
GlobeNewswire
Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026
September 30, 2026
From
Abivax
Via
GlobeNewswire
Abivax Presents Business Updates and First Half 2026 Financial Results
September 21, 2026
From
Abivax
Via
GlobeNewswire
Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod
July 30, 2026
From
Abivax
Via
GlobeNewswire
Abivax Strengthens Commercial Capabilities With Strategic Leadership Appointments
July 23, 2026
From
Abivax
Via
GlobeNewswire
Abivax Announces Closing of $920 Million Public Offering
July 06, 2026
From
Abivax
Via
GlobeNewswire
Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M)
July 02, 2026
From
Abivax
Via
GlobeNewswire
Correction: Abivax Announces Pricing of Highly Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares
July 01, 2026
From
Abivax
Via
GlobeNewswire
Abivax announces trading resumption of its ordinary shares on Euronext Paris
July 01, 2026
From
Abivax
Via
GlobeNewswire
Abivax Announces Pricing of Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares
July 01, 2026
From
Abivax
Via
GlobeNewswire
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
July 01, 2026
From
Abivax
Via
GlobeNewswire
Abivax Announces Launch of Public Offering of American Depositary Shares
June 30, 2026
From
Abivax
Via
GlobeNewswire
Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory Ulcerative Colitis Patients and Strengthening the Phase 3 Maintenance Safety Database
June 29, 2026
From
Abivax
Via
GlobeNewswire
ABVX Investors Have Opportunity to Join Abivax S.A. Fraud Investigation with the Schall Law Firm
June 17, 2026
From
Schall Law
Via
GlobeNewswire
ABVX Investors Have Opportunity to Join Abivax S.A. Fraud Investigation with the Schall Law Firm
June 10, 2026
From
Schall Law
Via
GlobeNewswire
ABVX Investors Have Opportunity to Join Abivax S.A. Fraud Investigation with the Schall Law Firm
June 03, 2026
From
The Schall Law Firm
Via
Business Wire
Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis
June 01, 2026
From
Abivax
Via
GlobeNewswire
Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis
May 22, 2026
From
Abivax
Via
GlobeNewswire
Abivax Announces Results of its May 11, 2026 Annual General Meeting
May 11, 2026
From
Abivax
Via
GlobeNewswire
Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares
May 05, 2026
From
Abivax
Via
GlobeNewswire
Abivax to Present Data on Obefazimod at Digestive Disease Week®
April 22, 2026
From
Abivax
Via
GlobeNewswire
Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents
April 20, 2026
From
Abivax
Via
GlobeNewswire
Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies
April 01, 2026
From
Abivax
Via
GlobeNewswire
Abivax Announces Full Year 2025 Financial Results and Provides Business Updates
March 23, 2026
From
Abivax
Via
GlobeNewswire
Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026
February 21, 2026
From
Abivax
Via
GlobeNewswire
Abivax Provides 2026 Corporate Outlook
January 07, 2026
From
Abivax
Via
GlobeNewswire
Abivax to be Added to Nasdaq Biotechnology Index
December 18, 2025
From
Abivax
Via
GlobeNewswire
Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings
December 17, 2025
From
Abivax
Via
GlobeNewswire
Abivax Presents Third Quarter 2025 Financial Results
December 15, 2025
From
Abivax
Via
GlobeNewswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1